Boehringer Ingelheim Licenses Synaffix’s Technology to Boost its ADC Portfolio in Oncology
Shots:
- BI has entered into an agreement with Synaffix (Lonza’s company) to license the latter’s ADC technology, boosting its oncology pipeline via NBE Therapeutics (BI’s subsidiary)
- As per the terms, BI will access Synaffix’s platform for a specified but undisclosed number of targets, with the first target nominated & others to follow within a predefined timeframe in exchange for an upfront, milestones of ~$1.3B & net-sales-based royalties
- Synaffix’s clinically validated platform modifies native glycan anchor sites on antibodies via enzymes to develop ADCs or BsAbs
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim & Synaffix
Related News:- Boehringer Ingelheim Introduces Vetmedin Solution (Pimobendan Oral Solution), for Congestive Heart Failure in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
